Novartis to Wind Down San Diego Technical Research and Development Site by Mid-2025

1. Site Closure: Novartis is planning a phased exit of its technical research and development (TRD) site in San Diego, which will be complete by mid-2025.
2. Layoffs: The closure will eliminate about 100 jobs, with 29 employees already laid off in the first phase.
3. Reason: The move is part of a broader restructuring of Novartis' drug development segment to drive sustainable R&D performance and bring medicines to patients faster.
4. Consolidation: The company will consolidate TRD capabilities at existing U.S. locations.
5. Remaining Presence: Novartis will maintain a research presence in San Diego with a team of approximately 580 associates at other locations.
6. Global Impact: The restructuring will also involve cutting about 680 roles in Novartis' development organization globally, with 440 jobs in Switzerland and 240 in the United States over the next two to three years.